Head-to-head evidence
Camizestrant vs Vepdegestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Camizestrant
Marketed by AstraZeneca
NCT04588298 · Phase 2 · completed
Although participants were randomized among camizestrant dose groups, the study was open-label and had no placebo or active comparator; the primary endpoint was a surrogate biomarker, change in tumor ER expression, rather than a clinical outcome. Reported ER expression decreased across groups, but there was no controlled primary endpoint comparison to establish treatment benefit.
Next expected readout: April 2027 · NCT05774951 (registry estimate)
Vepdegestrant
Marketed by Rigel Pharmaceuticals and partners
NCT04072952 · Phase 1/2 · completed
The study enrolled 219 participants but was non-randomized, open-label, and lacked a control group; its primary outcomes focused mainly on dose-limiting toxicities, adverse events, and laboratory abnormalities rather than a controlled efficacy comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT05573555 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camizestrant's landscape · Vepdegestrant's landscape